News By Tag
News By Place
Endometriosis Therapeutics- Pipeline Assessment and Market Forecasts to 2018
Endometriosis Therapeutics Market is Forecast to Show Steady Growth Until 2018
Current competition in the endometriosis therapeutics market is weak. The global endometriosis therapeutics market currently has hormonal therapy as the mainstay of treatment for endometriosis. At present, the treatment options are limited to gonadotropin-
(NSAIDs) and oral contraceptives (OCs) are prescribed off-label by physicians. Currently available pharmacological and surgical treatment options primarily target short term symptomatic relief and none of them is capable to treat the progression of the disease. Thus, the endometriosis therapeutics market has a high unmet need for therapies with higher efficacy and better and long-term safety as well as for disease modifying drugs. The market holds significant commercial potential for such novel therapies.
For Sample Pages, please click or add the below link to your browser:
Global Markets Direct’s analysis shows that the endometriosis developmental pipeline is weak with only 15 molecules in various phases of development, including six first-in-class molecules. These first-in-class molecules have a distinct advantage over the currently marketed products for endometriosis in terms of offering better symptomatic management but not with respect to treating the progression of the disease. The pipeline for endometriosis treatment includes GnRH antagonists, GnRH agonists, aromatase inhibitors (AIs), low-dose estrogen progestin, progesterone receptor selective blocker, steroid sulfatase inhibitor, neurokinin-3 (NK3) receptor antagonist, follicle stimulating hormone receptor (FSHR) negative
allosteric modulator (NAM) and others. The small developmental pipeline for endometriosis may not be able to bring in any paradigm shift in the treatment of endometriosis, till the forecast period, as most of the molecules with novel mechanism of action in the pipeline are in early phase of development, with only one molecule, NPC-01 (low-dose estrogen progestin), in Phase III of clinical development in Japan.
Global Markets Direct, the industry analysis specialist, has released its new report, “Endometriosis Therapeutics-
For further details, please click or add the below link to your browser:
Visit our report store: http://www.globalmarketsdirect.com
For more details contact:
North America: +1 646 395 5477